Capricor Therapeutics (NASDAQ:CAPR) Announces Earnings Results, Misses Expectations By $0.11 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11), FiscalAI reports.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded down $0.15 on Thursday, reaching $33.42. The company’s stock had a trading volume of 1,227,913 shares, compared to its average volume of 1,332,481. Capricor Therapeutics has a 1-year low of $4.30 and a 1-year high of $40.37. The business’s 50-day moving average price is $25.57 and its two-hundred day moving average price is $16.24. The firm has a market cap of $1.85 billion, a PE ratio of -18.57 and a beta of 0.37.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the company. State of Wyoming grew its stake in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares in the last quarter. Royal Bank of Canada increased its holdings in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. Russell Investments Group Ltd. increased its position in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the period. Tower Research Capital LLC TRC raised its holdings in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the last quarter. Finally, Orion Porfolio Solutions LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $239,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CAPR has been the subject of several recent analyst reports. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Oppenheimer increased their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. UBS Group set a $50.00 price objective on Capricor Therapeutics in a report on Monday, December 15th. Finally, iA Financial set a $48.00 target price on Capricor Therapeutics in a report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumes review of deramiocel and lifts prior hold — the agency has reopened the BLA review for deramiocel, a major regulatory catalyst that increases the probability of eventual approval and sets a formal decision timeline. Read More.
• Positive Sentiment: Late-breaking Phase 3 HOPE-3 data show clinically meaningful functional benefits — additional analyses presented at the 2026 MDA conference strengthen the therapy’s efficacy story in DMD, which supports both approval probability and long-term commercial potential. Read More.
• Positive Sentiment: Clinical signals extend to cardiac endpoints — coverage and reporting of HOPE-3 show improvements in key heart-function measures, an important commercial and safety consideration for DMD patients. Read More.
• Positive Sentiment: Analyst support — HC Wainwright reiterated a Buy, which can help sentiment and retail/institutional interest as regulatory clarity improves. Read More.
• Neutral Sentiment: Upcoming earnings and near-term catalysts — Capricor is projected to post quarterly results soon; earnings and management commentary can influence the short-term move. Read More.
• Neutral Sentiment: Short-interest data are muddled — recent reports show anomalous/zero short-interest figures and effectively no days-to-cover; unclear impact on squeeze dynamics or selling pressure. (Data summary)
• Negative Sentiment: Regulatory risk remains — the FDA previously issued a Complete Response Letter; resumption of review does not guarantee approval and the agency’s prior objections underscore execution risk and binary regulatory outcomes. Read More.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.